

# SOURCES OF FIGURES AND TABLES

## Figures

- 1.1 & 1.2 GLOBOCAN 2000\*  
1.3 WHO/TDR Image Library/Crump  
1.4 GLOBOCAN 2000\*  
1.5 CDC Public Health Image Library, Atlanta, USA/Dr. Edwin P. Ewing, Jr.  
1.6 Anna White, Coordinator, Global Partnerships for Tobacco Control, PO Box 19405, Washington, DC 20036, USA  
1.7 & 1.8 GLOBOCAN 2000\*  
1.9 & 1.10 IARCPress  
2.1 A. J. Sasco, IARC  
2.2 B.W. Stewart, Australia  
2.3 SPL/Cosmo  
2.4 WHO Digital Photo Library/H. Anenden  
2.5 Reprinted from *Eur J Cancer*, Vol. 35, F. Levi, F. Lucchini, E. Negri, P. Boyle, C. La Vecchia C, Cancer mortality in Europe, 1990-94, and an overview of trends from 1955 to 1994, 1477-1516, copyright 1999, with permission from Elsevier Science  
2.6 P. Boffetta, IARC/American Cancer Society, E.C. Hammond (1966) *Natl Cancer Inst Monogr*, 19:127-204; T. Hirayama (1985) A cohort study of cancer in Japan. In Blot WJ, Hirayama T, Hoel DG eds. *Statistical Methods in Cancer Epidemiology*. Hiroshima, Radiation Effects Research Foundation, 73-91  
2.7 Reprinted from *Eur J Cancer Prev*, Vol. 8, M. Pandey, A. Mathew, M.K. Nair, Global perspective of tobacco habits and lung cancer: a lesson for third world countries, 271-279, Copyright 1999, with permission from Elsevier Science  
2.8 Adapted from C.J.L. Murray et al., Tobacco, in C.J.L. Murray and A.D. Lopez (1996) *Quantifying Global Health Risks: the Burden of Disease Attributable to Selected Risk Factors*. Cambridge, Harvard University Press  
2.9 A.D. Lopez N.E. Collishaw, T. Piha (1994) A descriptive model of the cigarette epidemic in developed countries. *Tobacco Control*, 3:242-247, with permission from the BMJ Publishing Group  
2.10 P. Boffetta, IARC  
2.11 A.M. Thompson, UK  
2.12 P. Boffetta, IARC/ *IARC Monographs* Programme  
2.13 D. Jernigan, Marin Institute, California, USA  
2.14 Adapted from A.J. Tuyns, J. Estève, L. Raymond, F. Berrino, E. Benhamou et al. (1988) Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France), *Int J Cancer*, 41(4):483-491  
2.15 D. Jernigan, Marin Institute, California, USA  
2.16 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA  
2.17 - 2.19 IARCPress  
2.20 Groupe Charbonnages de France; HBL Audiovisuel/ Synchro  
2.21 & 2.22 IARCPress  
2.23 Pan Photographics, Via Le Pietre 15, Vico Equense, NA 80069, Italy  
2.24 WHO Digital Image Library/PAHO/Armando Waak  
2.25 Pascale Dia, IARC  
2.26 WHO Digital Image Library/H. Anenden  
2.27 - 2.31 R. Montesano, IARC  
2.32 IARCPress/T.W. Kensler, Department of Environmental Health Sciences, Johns Hopkins School of Hygiene and Public Health, Baltimore, MD 21205, USA  
2.33 H. Ohgaki, IARC  
2.34 Wellcome Trust Medical Photographic Library, UK  
2.35 IARCPress  
2.36 "Chernobilinterinform" 1996, 255620 Chernobilinterin - form, 1996 (25560, Chernobil, Kiev region, B. Chmelnitcky street, 1a)  
2.37 Pan Photographics, Via Le Pietre 15, Vico Equense, NA 80069, Italy  
2.38 NRPB (2001) *ELF Electromagnetic fields and he risk of cancer*, Vol. 12. No. 1, National Radiological Protection Board, Chilton Didcot, Oxon OX11 OPQ, UK  
2.39 H. N. Ananthaswamy, Department of Immunology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, USA  
2.40 USA Environmental Protection Agency  
2.41 Public Health Image Library CDC, USA/Dr Erskine Palmer  
2.42 Wellcome Trust Medical Photographic Library, UK  
2.43 By permission of Oxford University Press, H. zur Hausen (2000) Papillomaviruses causing cancer, *J Natl Cancer Inst*, 92(9): 695. Adapted from H. zur Hausen (1991) Human Papillomaviruses in the Pathogenesis of Anogenital Cancer, *Virology*, 184, 9-13.  
2.44 & 2.45 IARCPress  
2.46 Public Health Image Library, CDC, USA/Dr Edwin P. Ewing, Jr.  
2.47 & 2.48 S. Franceschi, IARC  
2.49 Copyright of the American Society for Investigative Pathology. F. Chisari (2000), Viruses, Immunity and Cancer: Lessons from Hepatitis B, *Am J Pathol*, 156, 1118-1131  
2.50 IARCPress  
2.51 Public Health Image Library, CDC, USA/Dr Edwin P. Ewing, Jr.  
2.52 Istituto Nazionale dei Tumori, Milan, Italy; Deutsches Krebsforschungszentrum, Heidelberg, Germany; National Institute of Public Health and Environmental Protection (RIVM), Bilthoven, Netherlands

- 2.53 T. Norat and E. Riboli, IARC
- 2.54 D. Graham, USA/Adapted from Fig. 2, S. Tsugane, M. Akabane, T. Inami, S. Matsushima, T. Ishibashi et al. (1991) Urinary salt excretion and stomach cancer mortality among four Japanese populations. *Cancer Causes Control*, 2:165-8, with kind permission of Kluwer Academic Publishers
- 2.55 IARCPress
- 2.56 B.W. Stewart, Australia
- 2.57 EPIC study/Dr Riboli, IARC
- 2.58A Map derived from FAO food consumption statistics/ T. Norat, E. Riboli, IARC.
- 2.58B GLOBOCAN 2000\*
- 2.59 Public Health Image Library, CDC, USA/James Gathany
- 2.60 Courtesy of the Multi-Organ Transplant Programme, UK
- 2.61 & 2.62 N.L. Harris, Department of Pathology, Warren 2, Massachusetts General Hospital, Fruit Street, Boston, MA 02114, USA
- 2.63 R.D. Brunning, Department of Laboratory Medicine and Pathology, University of Minnesota Hospital, 420 Delaware Street SE, Box 609, Minneapolis, MN 55455-0385, USA
- 2.64 C. A. Clarke (2001) Changing incidence of KS and NHL among young men in San Francisco, *AIDS*, 15(14): 1913-1914, copyright Lippincott Williams & Wilkins
- 2.65 E.J. Stanbridge and W. K. Cavenee, Tumor Suppressor Genes, in, R. Weinberg, ed (1989) *Oncogenes and the Molecular Origins of Cancer*, Cold Spring Harbor Laboratory Press
- 2.66 & 2.67 Wellcome Trust Medical Photographic Library, UK.
- 2.68 C. Bonnardel, IARC
- 2.69 IARCPress
- 2.70 Wellcome Trust Medical Photographic Library, UK
- 2.71 Reprinted with permission from Elsevier Science. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies, *Lancet*, 347, 1713-27
- 2.72 WHO/TDR Image Library/Crump
- 3.1 C. Harris, National Cancer Institute, NIH, Bethesda, MD 20892-4255, USA
- 3.2 E.R. Fearon and B. Vogelstein (1990) A genetic model for colorectal tumorigenesis, *Cell*, 61: 759-767
- 3.3 Reprinted from *Eur J Cancer*, Vol. 35(3), M. Ilyas, J. Straub, IP Tomlinson, W.F. Bodmer, Genetic pathways in colorectal and other cancers, 335-35, Copyright (1999), with permission from Elsevier Science
- 3.4 Y. Nakanuma, Second Department of Pathology, Kanazawa University School of Medicine, Takaramachi 13-1 920-8640
- 3.5 L.H. Sobin, USA
- 3.6 N.J. Carr, Department of Cellular Pathology, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK
- 3.7 A. Barbin, IARC
- 3.8 B.W. Stewart, Australia
- 3.9 - 3.11 Reprinted with permission from *Nature*. J.H. Hoeijmakers (2001) Genome maintenance mechanisms for preventing cancer. *Nature* 411, 366-374, Copyright (2001) Macmillan Magazines Ltd.
- 3.12 J.R. Jass, Pathology Department, Grad. Med. School, University of Queensland, Herston Road, 4006 Brisbane, Queensland, Australia
- 3.13 Adapted from C.R. Boland, F.A. Sinicrope, D.E. Brenner, J.M. Carethers (2000) Colorectal cancer prevention and treatment. *Gastroenterology*, 118(2 Suppl 1): S115-28
- 3.14 J. Hall, IARC
- 3.15 P. Hainaut, IARC
- 3.16 B. W. Stewart, Australia.
- 3.17 Courtesy of J. Couturier, Unité de Cytogénétique, Institut Curie, 26, rue d'Ulm, 5248 Paris, France
- 3.18 Adapted from P.H. Rabbitts, Tumour suppressor genes, in J. Kendrew and E. Lawrence, eds (1994) *The Encyclopaedia of Molecular Biology*, Blackwell Science
- 3.19 P. Hainaut, IARC
- 3.20 L'oréal Recherche, Centre Charles Zviak, 92583 Clichy, France
- 3.21 P. Hainaut, IARC
- 3.22 P. Hainaut, IARC/RasMol software, version 2.6; coordinate file for p53:DNA crystal data 1TUP in the Protein Brookhaven Database. Data from Y. Cho, S. Gorina, P.D. Jeffrey, N.P. Pavletich. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations (1994) *Science*, 265(5170): 346-355
- 3.23 P. Hainaut, IARC
- 3.24 P. Hainaut, IARC/IARC TP53 gene mutation database, R6, 2002
- 3.25 C.A. Rubio, Gastrointestinal and Liver Pathology, Department of Pathology, Karolinska Institute, 171 76 Stockholm, Sweden
- 3.26 S. Zeitlin and K. Sullivan, Department of Cell Biology, The Scripps Research Institute 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
- 3.27 & 3.28 P Hainaut, IARC
- 3.29 J.W. Shay, W.E.Wright, University of Texas Southwestern Medical Center, Department of Cell Biology Room K2-206 5323 Harry Hines Boulevard, Dallas, TX 75390-9039, USA. The centromere and telomere probes were provided by S. Gryaznov at the Geron Corporation, Menlo Park, CA, and the digital image was taken by Y. Zou
- 3.30 & 3.31 H. Yamasaki, Japan
- 3.32 M. Mesnil and H. Yamasaki (2000) Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap junctional intercellular communication. *Cancer Res*, 60: 3989-3999
- 3.33 J. F.R. Kerr and B.V. Harmon (1991) Definition and inci-

- dence of apoptosis, in *Apoptosis: the Molecular Basis of Cell Death*, eds L.D. Tomei and F.O. Cope. Cold Spring Harbour Laboratory Press, 5-29
- 3.34 Reprinted with permission from *Nature*. B.B. Zhou, S.J. Elledge (2000) The DNA damage response: putting checkpoints in perspective. *Nature*, 408: 433-439, Copyright (2000) Macmillan Magazines Ltd.
- 3.35 IARCPress
- 3.36 N.J. Carr, Department of Cellular Pathology, Southampton General Hospital, Tremona Road. Southampton SO16 6YD, UK
- 3.37 Reprinted with permission from *Nature*, M.O. Hengartner (2000) The biochemistry of apoptosis, *Nature*, 407, 770-6. Copyright (2000) Macmillan Magazines Ltd.
- 3.38 J.C. Bourdon, Department of Surgery and Molecular Oncology, Ninewells Hospital, University of Dundee, Scotland, UK
- 3.39 Adapted from A.A. Adjei, USA
- 3.40 Reprinted from *Eur J Cancer*, Vol. 36, Beavon I, The E-cadherin complex in tumour metastasis: structure , function, regulation, 1607-1620. Copyright (2000), with permission from Elsevier Science
- 3.41 Reprinted from *Eur J Cancer*, Vol. 36, J.A. Wyke, Overview-burgeoning promise in metastasis research, 1589-1594. Copyright 2000, with permission from Elsevier Science
- 3.42 C. Fenoglio-Preiser, Department of Pathology, University of Cincinnati, School of Medicine, 231 Bethesda Avenue, POB 670529, Cincinnati, OH 45267-0529, USA
- 3.43 R.C. Janzer, Division of Neuropathology, University Institute of Pathology, 27 rue du Bugnon, CH 1011 Lausanne, Switzerland
- 3.44 R.D. Rubens, Clinical Oncology Unit, Guys Hospital, London SE1 9RT, UK
- 3.45 S. Eccles, UK
- 4.1 Reprinted from R. Doll, R. Peto, K. Wheatley, R. Gray, I. Sutherland (1994) Mortality in relation to smoking: 40 years' observations on male British doctors. *BMJ*, 309(6959): 901-911, with permission from the *BMJ* Publishing Group
- 4.2 Adapted from F. Faggiano, T. Partanen, M. Kogevinas, P. Boffetta (1997) *Socioeconomic differences in cancer incidence and mortality* (IARC Scientific Publication 138), 65-176.
- 4.3 R. Peto, S. Darby, H. Deo, P. Silcocks, E. Whitley et al. (2000) Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. *BMJ*, 321(7257): 323-329.with permission from the *BMJ* Publishing Group
- 4.4 T. Lancaster, L. Stead, C. Silagy, A. Sowden (2000) Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. *BMJ*, 321(7257): 355-358, with permission from the *BMJ* Publishing Group. Original data from Silagy et al. (2000) *Nicotine replacement therapy for smoking cessation*, Cochrane Library, Issue 3, Oxford: Update Software
- 4.5 R. Peto, Z.M. Chen, J. Boreham (1999) Tobacco the growing epidemic. *Nat Med* 5 (1);15-17 and B.Q. Liu, R. Peto, Z.M. Chen, J. Boreham, Y.P. Wu et al. (1998) Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. *BMJ*, 317(7170):1411-22
- 4.6 "La vérité si j'fume" courtesy of la Fédération Nationale des Centres de Lutte Contre le Cancer and Aventis Pharma SA; "Il suffit de dire NON", courtesy of the Association Tunisienne de Lutte Contre le Cancer; "Quanto ti costa fumare?", Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; "Merci de ne pas fumer" & "Animals Smoking", copyright of Comité National Contre le Tabagisme, 31, avenue Michel Bizot, 75012 Paris, France, [www.cnct.org](http://www.cnct.org); "NO smoking", courtesy of the Japan Public Health Association. A. J. Sasco, IARC
- 4.7 Centers for Disease Control and Prevention (2000) *Mortality and Morbidity Weekly Report*, 49:1066-1069, <http://www.cdc.gov/mmwr>
- 4.8 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 4.9 P. Boffetta, IARC/Adapted from K. Magnus, A. Andersen, A.C. Hogetveit (1982) Cancer of respiratory organs among workers at a nickel refinery in Norway. *Int J Cancer*, 30(6): 681-685
- 4.10 Reprinted with permission from Elsevier Science, J. Peto, J.T. Hodgson, F.E. Matthews, J.R. Jones (1995) Continuing increase in mesothelioma mortality in Britain. *Lancet*, 345(8949): 535-539
- 4.11 Anti-Cancer Council of Victoria, Australia/IARCPress
- 4.12 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 4.13 The Cancer Council New South Wales and the NSW Health Department, Australia
- 4.14 GLOBOCAN 2000\*
- 4.15 & 4.16 WHO (2000) Vaccines, Immunization and Biologicals, 1997 data <http://www.who.int/vaccines/surveillance/graphics/htmls/hepbprev.htm> and <http://www.who.int/vaccines/surveillance/graphics/htmls/hepb.htm>
- 4.17 J.Y. Scoazec, France
- 4.18 G. Kirk, USA/Adapted from P. Pisani, D.M. Parkin, N. Muñoz, J. Ferlay (1997) Cancer and infection: estimates of the attributable fraction in 1990. *Cancer Epidemiol Biomarkers Prev*, 6(6): 387-400
- 4.19 G.Kirk, USA.
- 4.20 IARCPress
- 4.21 W.J. Edmunds, G.F. Medley, D.J. Nokes, A.J. Hall and H.C. Whittle (1993) The influence of age on the development of the hepatitis B carrier state. *Proc R Soc Lond B*, 253, 197-201. With permission from The Royal Society.
- 4.22 - 4.24 IARCPress
- 4.25 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 4.26 C.R. Boland, F.A. Sinicrope, D.E. Brenner, J.M. Carethers (2000) Colorectal cancer prevention and treatment.

- Gastroenterology*, 118(2 Suppl 1): S115-28, with the permission of W.B. Saunders Company
- 4.27 IARCPress
- 4.28 B. Marincek, Institut für Diagnostische Radiologie, UniversitätsSpital, Ramistrasse 100, CH-8091 Zürich, Switzerland
- 4.29 R. Sankaranarayanan, IARC
- 4.30 Copyright GE Medical Systems
- 4.31 P. Pisani, IARC
- 4.32 D.M. Parkin et al. (2001) Eur J Cancer, 37, suppl.8: S4-66
- 4.33 A. M. Thompson, UK
- 4.34 Wellcome Trust Medical Photographic Library, UK
- 4.35 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 4.36 Reprinted from *Radiol Clin North Am*, 38, L. Tabar, B. Vitak, H.H. Chen, S.W. Duffy, M.F. Yen et al., The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up, 625-651, copyright (2000), with permission from Elsevier Science
- 4.37 Wellcome Trust Medical Photographic Library, UK
- 4.38 D.M. Parkin et al. (2001) Eur J Cancer, 37, suppl.8: S4-66
- 4.39 R. LiPuma, Prostate Cancer Education Council, 300 South Jackson Street, Suite 540 Denver, CO 80209, USA.
- 4.40 C.A. Rubio, Gastrointestinal and Liver Pathology, Department of Pathology, Karolinska Institute, 171 76 Stockholm, Sweden
- 4.41 D.M. Parkin et al. (2001) Eur J Cancer, 37, suppl.8: S4-66
- 4.42 Prévention et Biologie, SA, 29-33 Rue de Metz, 94170 Le Perreux, France
- 4.43 D.M. Parkin et al. (2001) Eur J Cancer, 37, suppl.8: S4-66
- 4.44 IARCPress
- 4.45 D.M. Parkin et al. (2001) Eur J Cancer, 37, suppl.8: S4-66
- 4.46 Adapted from M.R. Law, J.K. Morris, N.J. Wald (1999) The importance of age in screening for cancer. *J Med Screen*, 6(1): 16-20, with permission from the BMJ Publishing Group
- 4.47 R. Sankaranarayanan, IARC
- 4.48 IARCPress
- 4.49 - 4.52 R. Sankaranarayanan, IARC
- 4.53 A & B H. Ohgaki, IARC
- 4.53C R. Lambert, IARC
- 4.54 D.M. Parkin et al. (2001) Eur J Cancer, 37, suppl.8: S4-66
- 4.55 Adapted from Table 2, Y. Tsubono and S. Hisamichi (2000) Screening for gastric cancer in Japan. *Gastric cancer*, 3: 9-18. Copyright Springer-Verlag
- 5.1 GLOBOCAN 2000\*
- 5.2 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 5.3 B.W. Stewart, Australia
- 5.4 D.M. Parkin et al. (2001) Eur J Cancer, 37, suppl.8: S4-66
- 5.5 J.A. Baron and T.E. Rohan, Tobacco, in D. Schottenfeld and J.F. Fraumeni Jr. eds (1996) *Cancer Epidemiology and Prevention*, 2nd edition, Oxford University Press, UK
- 5.6 P. Boffetta, IARC/Adapted from J.H. Lubin, W.J. Blot (1984) Assessment of lung cancer risk factors by histologic category. *J Natl Cancer Inst*, 73: 383-389
- 5.7 B. Marincek, Institut für Diagnostische Radiologie, UniversitätsSpital, Ramistrasse 100, CH-8091 Zürich, Switzerland
- 5.8 F. Berger and J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France
- 5.9 P. Boffetta, IARC
- 5.10 IARC/SEER/Osaka Cancer Registry†
- 5.11 IARCPress/Department of Pathology, University of Zurich, Switzerland
- 5.12 GLOBOCAN 2000\*
- 5.13 Wellcome Trust Medical Photographic Library, UK
- 5.14 Von Kantor & Associates Inc., Ft. Lauderdale FL, USA/www.lectureslides.com
- 5.15 A. M. Thompson, UK
- 5.16 & 5.17 F. Berger and J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France
- 5.18 P. Kleihues, IARC
- 5.19 D.M. Parkin et al. (2001) Eur J Cancer, 37, suppl.8: S4-66
- 5.20 Von Kantor & Associates Inc., Ft. Lauderdale FL, USA/www.lectureslides.com
- 5.21 IARC/SEER/Osaka Cancer Registry†
- 5.22 IARCPress
- 5.23 GLOBOCAN 2000\*
- 5.24 D.M. Parkin et al. (2001) Eur J Cancer, 37, suppl.8: S4-66
- 5.25 N. Matsukura, Japan
- 5.26 H. Ohgaki, IARC
- 5.27 F. Berger and J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France
- 5.28 IARC/SEER/Osaka Cancer Registry†
- 5.29 GLOBOCAN 2000\*
- 5.30 IARCPress
- 5.31 Reprinted from European Journal of Cancer, Vol 35, No 3, Ilyas M, Straub J, Tomlinson IPM, Bodmer W, Genetic pathways in colorectal and other cancers, 335-351, copyright (1999), with permission from Elsevier Science
- 5.32 - 5.34 F. Berger and J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France
- 5.35 C. Fenoglio-Preiser, Department of Pathology, University of Cincinnati, School of Medicine, 231 Bethesda Avenue, POB 670529, Cincinnati, OH 45267-0529, USA
- 5.36 IARC/SEER/Osaka Cancer Registry†
- 5.37 & 5.38 GLOBOCAN 2000\*
- 5.39 IARCPress
- 5.40 B. Marincek, Institut für Diagnostische Radiologie, UniversitätsSpital, Ramistrasse 100, CH-8091 Zürich, Switzerland
- 5.41 - 5.43 F. Berger and J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Herriot, place d'arsonval, 69437 Lyon

- 5.44** IARC/SEER/Osaka Cancer Registry†  
**5.45** GLOBOCAN 2000\*  
**5.46** D.M. Parkin et al. (2001) Eur J Cancer, 37, suppl.8: S4-66  
**5.47** L. Denis, Belgium, and K. Griffiths, UK  
**5.48 & 5.49** F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, place d'Arsonval, 69437 Lyon France  
**5.50** Adapted from Figure 4C. Abate-Shen, M.M. Shen (2000) Molecular genetics of prostate cancer. *Genes Dev*, 14(19): 2410-2434  
**5.51** GLOBOCAN 2000\*  
**5.52** P. Kleihues, IARC  
**5.53** M.K. Rosenblum, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York NY 10021, USA  
**5.54** F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, place d'Arsonval, 69437 Lyon France  
**5.55** Adapted from Figure 6, R.S. Chaganti, J. Houldsworth (2000) Genetics and biology of adult human male germ cell tumors. *Cancer Res*, 60(6): 1475-1482  
**5.56** IARC/SEER/Osaka Cancer Registry†  
**5.57** GLOBOCAN 2000\*  
**5.58** WHO/TDR Image Library/Crump  
**5.59 & 5.60** R. Sankaranarayanan, IARC  
**5.61** F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France  
**5.62** IARC/SEER/Osaka Cancer Registry†  
**5.63** GLOBOCAN 2000\*  
**5.64** F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France  
**5.65** IARC/SEER/Osaka Cancer Registry  
**5.66** M. Esteller, J. Xercavins, J. Reventos (1999) Advances in the molecular genetics of endometrial cancer. *Oncology Reports* 6 (6): 1377-1382  
**5.67** GLOBOCAN 2000\*  
**5.68** B. Marincek, Institut für Diagnostische Radiologie, UniversitätsSpital, Ramistrasse 100, CH-8091 Zurich, Switzerland  
**5.69** Wellcome Trust Medical Photographic Library, UK  
**5.70** F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France  
**5.71** IARC/SEER/Osaka Cancer Registry†  
**5.72** GLOBOCAN 2000\*  
**5.73 & 5.74** IARC Press  
**5.75** D.M. Parkin et al. (2001) Eur J Cancer, 37, suppl.8: S4-66  
**5.76** A.M. Thompson, UK  
**5.77** F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France  
**5.78** C. Fenoglio-Preiser, Department of Pathology, University of Cincinnati, School of Medicine, 231 Bethesda Avenue, POB 670529, Cincinnati, OH 45267-0529, USA  
**5.79** M. Werner, Institute of Pathology, Technische Universität München, Ismaninger Strasse 22, D-81675 Munich, Germany  
**5.80** IARC/SEER/Osaka Cancer Registry†  
**5.81** GLOBOCAN 2000\*  
**5.82** P. Brennan, IARC/ Adapted from P. Brennan, O. Bogillot, S. Cordier et al. (2000) Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. *Int J Cancer*, 86(2): 289-294  
**5.83** WHO/TDR Image Library/ Manderson  
**5.84 & 5.85** F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France  
**5.86** Reprinted from *Urologic Clinics of North America*, 27(1), R. Lee and M.J. Droller, The natural history of bladder cancer, 1-13, copyright (2000), with permission from Elsevier Science  
**5.87** IARC/SEER/Osaka Cancer Registry†  
**5.88 - 5.90** GLOBOCAN 2000\*  
**5.91 - 5.93** R. Sankaranarayanan, IARC  
**5.94** F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France  
**5.95** IARC/SEER/Osaka Cancer Registry†  
**5.96** D. Sidransky (1997) Tumor suppressor genes, in V.T. DeVita Jr., et al., eds, *Cancer: Principles and Practice of Oncology*, 5th edition, Lippincott-Raven, p 737  
**5.97** GLOBOCAN 2000\*  
**5.98** Wellcome Trust Medical Photographic Library, UK  
**5.99** L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller, L. Clegg, B.K. Edwards eds (2001) *SEER Cancer Statistics Review, 1973-1998*, National Cancer Institute, Bethesda, MD  
**5.100** GLOBOCAN 2000\*  
**5.101** E.S. Jaffe, Laboratory of Pathology, NIH, Building 10, Room 2N-202, 10 Center Drive MSC-1500, Bethesda, MD 20892-1500, USA  
**5.102** F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France  
**5.103** H. Stein, Institut für Pathologie, Freie Universität Berlin, Universitätsklinikum Steglitz, Hindenburgdamm 30, D 12200 Berlin, Germany  
**5.104** E.S. Jaffe, Laboratory of Pathology, NIH, building 10, Room 2N-202, 10 Center Drive MSC-1500, Bethesda, MD 20892-1500, USA  
**5.105** Reprinted by permission from A.A. Alizadeh, M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*, 403(6769): 503-511. Copyright 2000, Macmillan Magazines Ltd.

- 5.106 & 5.107 IARC/SEER/Osaka Cancer Registry†
- 5.108 GLOBOCAN 2000\*
- 5.109 Los Alamos National Laboratory/SPL/Cosmos
- 5.110 L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller et al., eds (2001) *SEER Cancer Statistics Review, 1973-1998*, National Cancer Institute, Bethesda MD, USA
- 5.111 A & B R.D. Brunning, Department of Laboratory Medicine and Pathology, University of Minnesota Hospital, 420 Delaware Street S.E., Box 609, Minneapolis, MN 55455-0385, USA
- 5.112 Adapted from a figure by J. Melo, Department of Haematology, ISCM, Hammersmith Hospital, Ducane Road, London W12 ONN, UK
- 5.113 A & B G. Flandrin, Laboratoire Central de Hématologie, Hôpital Necker, 149 rue de Sèvres, F-75743 Paris, France
- 5.114 R.D. Brunning, Department of Laboratory Medicine and Pathology, University of Minnesota Hospital, 420 Delaware Street S.E., Box 609, Minneapolis, MN 55455-0385, USA
- 5.115 With permission of J.A. Squire, from V.D. Markovic, D. Bouman, J. Bayani, J. Al-Maghrabi, S. Kamel-Reid et al. (2000) Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. *Leukemia*, 14(6):1157-1160
- 5.116 B. Hirsch, Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, 420 Delaware St. SE, Minneapolis, MN 55455, USA
- 5.117 J.W. Vardiman, Department of Pathology, University of Chicago Medical Center, 5841 South Maryland Ave., MC0008 Romm TW-055, Chicago, IL 60637-1470, USA
- 5.118 IARC/SEER/Osaka Cancer Registry†
- 5.119 & 5.120 GLOBOCAN 2000\*
- 5.121 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 5.122 G. Zamboni, Dept of Pathology, University of Verona, Strada Le Grazie, I-37134 Verona, Italy
- 5.123 G. Klöppel, Institute of Pathology, University of Kiel, Michaelistrasse 11, D-24105 Kiel, Germany
- 5.124 P. Vogt, Department of Pathology, University Hospital USZ, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland
- 5.125 F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France
- 5.126 IARC/SEER/Osaka Cancer Registry†
- 5.127 GLOBOCAN 2000\*
- 5.128 Data from New South Wales Central Cancer Registry†, Australia
- 5.129 B.W. Stewart, Australia
- 5.130 - 5.134 W. McCarthy, Australia
- 5.135 GLOBOCAN 2000\*
- 5.136 International Atomic Energy Agency, Vienna
- 5.137 GLOBOCAN 2000\*
- 5.138 International Atomic Energy Agency, Vienna
- 5.139 F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France
- 5.140 Adapted from Figure 2, D.L. Learoyd , M. Messina, J. Zedenius, B.G. Robinson (2000) Molecular genetics of thyroid tumours and surgical decision making. *World J Surg*, 24, 923-933
- 5.141 IARC/SEER/Osaka Cancer Registry†
- 5.142 & 5.143 GLOBOCAN 2000\*
- 5.144 Wellcome Trust Medical Photographic Library, UK
- 5.145 B. Marincek, Institut für Diagnostische Radiologie, UniversitätsSpital, Ramistrasse 100, CH-8091 Zurich, Switzerland
- 5.146 Public Health Image Library, CDC, USA/Dr Edwin P. Ewing, Jr.
- 5.147 F. Berger and J.Y. Scoazec, Laboratoire d'Anatomopathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69437 Lyon France
- 5.148 IARC/SEER/Osaka Cancer Registry†
- 5.149 J. Ferlay, F.I. Bray, R. Sankila, D.M. Parkin eds (1999) *EUCAN90: Cancer Incidence Mortality and Prevalence in the European Union (IARC Cancer Bases No. 4)*, Lyon, IARCPress
- 5.150 P. Kleihues, IARC
- 5.151 P.C. Burger, Pathology Building, Room 706, The Johns Hopkins Hospital, 600 Wolfe Street, Baltimore, MD 21287, USA
- 5.152 H. Ohgaki, IARC
- 5.153 P. Kleihues, IARC
- 5.154 A. Vital, Laboratory of Neuropathology, Victor Segalen University, Bordeaux 2, 146, rue Leo-Saignat, 33076 Bordeaux, France
- 6.1 Wellcome Trust Medical Photographic Library, UK
- 6.2 - 6.5 G. Maddern, Australia
- 6.6 Varian Medical Systems, Palo Alto, USA
- 6.7-6.8 Varian Medical Systems UK Ltd.
- 6.9 & 6.10 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 6.11 K. Sikora, UK
- 6.12 Modified from C.M. Haskell, ed (1995) *Cancer Treatment, 4th Edition*, W.B. Saunders/Reprinted from W.E. Ross et al., *Pharmacology and Therapeutics*, copyright 1987, Vol. 32, p. 89, with permission from Elsevier Science
- 6.13 H. Stein, Institut für Pathologie, Freie Universität Berlin, Universitätsklinikum Steglitz, Hindenburgdamm 30, D-12200 Berlin, Germany
- 6.14 K. Sikora, UK
- 6.15 A. Villunger and A. Strasser (1999) The great escape: is immune evasion required for tumor progression? *Nat Med*, 5(8): 874-5
- 6.16 P. Hersey, Australia
- 6.17 K.R. Dumon, H. Ishii, L.Y. Fong, N. Zanesi, V. Fidanza et al., (2001) FHIT gene therapy prevents tumor development in Fhit-

- deficient mice. *Proc Natl Acad Sci USA*, 98: 3346-3351. Copyright (2001) National Academy of Sciences, USA
- 6.18 Von Kantor and Associates Inc., Fort. Lauderdale FL, USA/www.lectureslides.com
- 6.19 A. M. Thompson, UK
- 6.20 Courtesy of the Palliative Care Council of South Australia
- 6.21 Adapted from WHO (1996) Cancer Pain Relief, 2nd edition, Geneva, World Health Organization/data for 1999 from David E. Joranson, Pain & Policy Studies Group, WHO Collaborating Center for Policy and Communications and the International Narcotics Control Board, United Nations Demographic Yearbook, 1999.
- 6.22 Data from David E. Joranson, Pain & Policy Studies Group, WHO Collaborating Center for Policy and Communications
- 6.23 B. Cassileth, USA
7. 1 & 7.2 IARCPress
- 7.3 C. Sepulvédá, WHO
- 7.4 International Union Against Cancer (UICC), 3, rue du Conseil-Général, CH-1205 Geneva, Switzerland
- 7.5 Tobacco Free Initiative (TFI), World Health Organization, Avenue Appia 20 1211, Geneva 27 Switzerland
- 7.6 M. Imperi (2000) *BMJ*, 321, cover photo, with permission from the *BMJ* Publishing Group.
- 7.7 E. Lucas, IARC
- 7.8 WHO/TDR Image Library/Haaland
- 7.9 R. Sankaranarayanan, IARC
- 7.10 G. Mollon, IARC
- 7.11 - 7.13 E. Lucas, IARC
- 7.14 WHO (1998) *The World Health Report 1998. Life in the 21st Century: A Vision for All*. Geneva, World Health Organization, p39
- 7.15 & 7.16 WHO/HPR/TDR Image Library/Crump
- 7.17 WHO (1998) *The World Health Report 1998. Life in the 21st Century: A Vision for All*. Geneva, World Health Organization, p44
- 7.18 Wellcome Trust Medical Photographic Library, UK
- 2.7 - 2.10 J. Rice, IARC/IARC Monographs Programme
- 2.11 P. Boffetta, IARC
- 2.12 P. Boffetta, IARC/WHO European Centre for Environment and Health, 1995
- 2.13 - 2.15 J. Rice, IARC/IARC Monographs Programme
- 2.16 IARCPress/UNSCEAR, 1994
- 2.17 E. Cardis, IARC
- 2.18 S. Franceschi, IARC
- 2.19 J. Rice, IARC/IARC Monographs Programme
- 2.20 & 2.21 D. Goldgar, IARC
- 2.22 S. Franceschi, F. Parazzini, E. Negri, M. Booth, C. La Vecchia, V. Beral, A. Tzonou and D. Trichopoulos (1991) Pooled analysis of 3 European case-control studies of epithelial ovarian cancer III. Oral contraceptive use. *Int J. Cancer*, 49: 61-65
- 3.1 Adapted from H. Marquardt, Chemical carcinogenesis, in H. Marquardt, S.G. Schafer, R. McClellan and F. Welsch, eds (1999). *Toxicology*, Academic Press, San Diego, 151-178
- 3.2 & 3.3 P. Hainaut, IARC
- 3.4 H. Yamasaki, Y. Omori, M.L. Zaidan-Dagli, N. Mironov, M. Mesnil et al. (1999) Genetic and epigenetic changes of intercellular communication genes during multistage carcinogenesis, *Cancer Detect and Prev*, 23: 273-279
- 3.5 & 3.6 S. Eccles, UK
- 3.7 Reprinted by permission from *Nature*, L.A. Liotta, E.C. Kohn (2001) The microenvironment of the tumour-host interface, *Nature*, 411: 375-379, copyright 2001, Macmillan Magazines Ltd.
- 3.8 A. Sasco, IARC
- 4.1 & 4.2 C.J.L. Murray, A.D. Lopez, Assessing the burden of disease that can be attributed to specific risk factors. In *Ad Hoc Committee on Health Research Relating to Future Intervention Options. Investing in Health Research and Development*. World Health Organization, Geneva, 1996
- 4.3 A. Sasco, IARC
- 4.4 IARC (1999) *Re-evaluation of some Organic Chemicals, Hydrazine and Hydrogen Peroxide* (IARC Monographs Vol. 71), Lyon, IARCPress
- 4.5 USA EPA (2000) *Latest Findings on National Air Quality: 1999 Status and Trends*, US Environmental Protection Agency
- 4.6 WHO (1999) *Air Quality Guidelines*, Geneva, WHO
- 4.7 S. Yamamura (2001) Drinking water guidelines and standards, in *United Nations synthesis report on arsenic in drinking water*, United Nations (draft), [http://www.who.int/water\\_sanitation\\_health/Arsenic/ArsenicUNReptoc.htm](http://www.who.int/water_sanitation_health/Arsenic/ArsenicUNReptoc.htm)
- 4.8 B.W. Stewart, Australia
- 4.9 Adapted from Table 1, Prophylactic vaccines under development, in A. Kols and J. Sherris (2000) *HPV Vaccines: Promise and Challenges*. Alliance for Cervical Cancer Prevention, PATH
- 4.10 & 4.11 S. Franceschi and N. Muñoz, IARC
- 4.12 H. Vainio, IARC
- 4.13 & 4.14 L. Denis, Belgium
- 4.15 & 4.16 R. Lambert, IARC

## Tables

- 2.1 & 2.2 Reprinted from *Eur J Cancer Prev*, Vol. 8, M. Pandey, A. Mathew, M.K. Nair. Global perspective of tobacco habits and lung cancer: a lesson for third world countries, 271-9, Copyright 1999, with permission from Elsevier Science
- 2.3 Adapted from N.J. Wald and A.K. Hackshaw (1996) *Br Med Bulletin*, 52 (1): 3-11 (and from the American Cancer Study (CPSII)), by permission of Oxford University Press
- 2.4 H. Boeing, Alcohol and risk of cancer of the upper gastrointestinal tract: first analysis of the EPIC data. In: E. Riboli and R. Lambert eds (2002) *Nutrition and Lifestyle: Opportunities for Cancer Prevention* (IARC Scientific Publications No. 156). Lyon, IARCPress
- 2.5 & 2.6 P. Boffetta, IARC

- 4.17** R. Lambert, IARC/Adapted from J.S. Mandel, J.H. Bond, T.R. Church, D.C. Snover, G.M. Bradley et al. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. *N Engl J Med*, 328:1365-1371
- 4.18** IARC Working Group on Cervical Cancer Screening (1986) Summary chapter, *Screening for Cancer of the Uterine Cervix*. (IARC Scientific Publication No. 76), Lyon, IARCPress
- 4.19** R. Sankaranarayanan, IARC
- 5.1** P. Boffetta, IARC
- 5.2** A. Sasco, IARC/Data from Table 36.2-23, Cancer of the Breast, in V.T. DeVita Jr. et al., eds (1997) *Cancer: Principles and Practice of Oncology*, 5th Edition, Lippincott-Raven
- 5.2 B** Munoz et al. *N Engl J Med* 348:518-527 (2003)
- 5.3** H. Ohgaki, IARC
- 5.4** L. Raymond, J. Young M. Parkin S. Whelan and J. Ferlay , (1997) *Cancer Incidence in Five Continents*, Vol. VII, IARCPress
- 5.5** L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller et al., eds (2001) *SEER Cancer Statistics Review, 1973-1998*, National Cancer Institute, Bethesda MD, USA
- 5.6 & 5.7** P. Hainaut, IARC
- 5.8** L. Denis, Belgium
- 5.9** T. Shimoda, Department of Clinical Laboratory, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo Ku, 104-0045 Tokyo, Japan
- 5.10** Adapted from Anon. (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood*, 89: 3909-3918
- 5.11** G. Young, Australia
- 5.12 & 5.13** G. Klöppel, Institute of Pathology, University of Kiel, Michaelistrasse 11, D-24105 Kiel, Germany
- 5.14** W. McCarthy, Australia
- 5.15** Data from E. van den Berg, T. Dijkhuizen (1999) Classification of renal cell cancer based on (cyto)genetic analysis. *Contrib Nephrol*, 128: 51-61; A. Bernheim, A. Vagner-Capodano, J. Couturier, et le Groupe Français de Cytogénétique Oncologique (2000) De la cytogenétique à la cytogenomie oncologique. *Médecine/Sciences*, 16: 528-539
- 5.16 & 5.17** P. Kleihues, IARC
- 6.1** Table 15-12, p301, S. Rosenberg, Principles of cancer management: surgical oncology, in V.T. DeVita Jr., S. Hellman, S.A. Rosenberg, eds (1997) *Cancer: Principles and Practice of Oncology*, 5th edition, copyright Lippincott, Williams & Wilkins
- 6.2** G.H. Sakorafas (2001) Breast cancer surgery—historical evolution, current status and future perspectives. *Acta Oncol*, 40(1): 5-18
- 6.3** A.J.A. Bremers, E.J.Th. Rutgers, C.J.H. van de Velde (1999) Cancer surgery: the last 25 years. *Cancer Treat Rev*, 25: 333-353
- 6.4 - 6.8** K. Sikora, UK
- 6.9** P. Hersey, Australia
- 6.10** Adapted from S.J. Clarke, Drug resistance, in J.F. Bishop, ed (1999) *Cancer Facts. A Concise Oncology Text*, Australia, Harwood Academic Publishers, 67-71
- 6.11** K. Shin, USA
- 6.12** J.A. DeLisa, *Cancer*, Vol. 92, No. 4 Suppl., 2001, pp. 970-974. Copyright (2001) American Cancer Society. Reprinted by permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.
- 6.13 & 6.14** K. Shin, USA
- 7.1 & 7.2** R. Sankaranarayanan, IARC

Note:

\* GLOBOCAN 2000 J. Ferlay, F.I. Bray, D.M. Parkin, P. Pisani (2001) *Globocan 2000: Cancer Incidence and Mortality Worldwide* (IARC Cancer Bases No. 5), Lyon, IARCPress.

† IARC/SEER/Osaka Cancer Registry.

R. Sankaranarayanan, R.J. Black and D.M. Parkin (1998) *Cancer survival in developing countries* (IARC publication No. 145), Lyon, IARCPress;

F. Berrino, R. Capocaccia, J. Esteve, F. Berrino, J. Capocaccia et al. (1999) *Survival of cancer patients in Europe: the EUROCARE-2 study* (IARC Publication No. 151), Lyon, IARCPress;

L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller et al., eds (2001) *SEER Cancer Statistics Review, 1973-1998*, National Cancer Institute. Bethesda, MD; [http://seer.cancer.gov/csr/1973\\_1999/](http://seer.cancer.gov/csr/1973_1999/) Osaka Cancer Registry, Japan: data for 1992 used. [http://www.mc.pref.osaka.jp/ocr\\_e/ocr/](http://www.mc.pref.osaka.jp/ocr_e/ocr/)